Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immunitybio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IBRX
Nasdaq
8731
https://immunitybio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immunitybio Inc
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
- Apr 25th, 2024 4:03 am
ImmunityBio's bladder cancer therapy wins FDA approval
- Apr 23rd, 2024 8:55 pm
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Apr 23rd, 2024 1:56 am
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
- Mar 6th, 2024 2:00 pm
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
- Mar 5th, 2024 2:00 pm
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
- Feb 21st, 2024 2:00 pm
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
- Feb 13th, 2024 10:17 am
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
- Feb 5th, 2024 2:00 pm
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
- Jan 2nd, 2024 11:00 am
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
- Nov 16th, 2023 2:00 pm
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
- Nov 7th, 2023 2:00 pm
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
- Oct 26th, 2023 1:00 pm
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
- Oct 23rd, 2023 1:00 pm
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
- Sep 11th, 2023 10:00 am
ImmunityBio, Inc. (NASDAQ:IBRX) Top Key Executive Patrick Soon-Shiong's holdings dropped 14% in value as a result of the recent pullback
- Sep 8th, 2023 2:55 pm
ImmunityBio Names Enrique Diloné as Chief Technology Officer
- Aug 3rd, 2023 1:00 pm
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
- Jul 21st, 2023 12:32 am
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
- Jul 10th, 2023 1:30 pm
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
- May 22nd, 2023 1:00 pm
Scroll